1 The Faculty of Medicine, Aalborg University, VBN2 Aalborg University Hospital, The Faculty of Medicine, Aalborg University, VBN3 Klinik Medicin, The Faculty of Medicine, Aalborg University, VBN4 Blodsygdomme (Hæmatologi), The Faculty of Medicine, Aalborg University, VBN5 Forskningsadministrationen, Aalborg Universitetshospital, The Faculty of Medicine, Aalborg University, VBN6 Forskningsenhed for Klinisk Sygepleje, The Faculty of Medicine, Aalborg University, VBN7 Department of Health Science and Technology, The Faculty of Medicine, Aalborg University, VBN
A living condition for haematological patients treated with chemotherapy
Introduction: Rehabilitation was introduced back in 1950-60, and has been accepted as part of comprehensive care aimed at patients with cardiac diseases for more than 20 years. There is well established evidence that rehabilitation improves quality of life, and physical and psychological functional level in cardiac patients. Further rehabilitation reduces re-hospitalization, and mortality, and are considered a cost-effective intervention in cardiac care. Rehabilitation services aimed at cardiac patients have been developed trough out the world during the last decade. Despite solid evidence a number of organizational challenges still exist in order to ensure rehabilitation services as part of comprehensive cardiac care. Parallel it has been documented that rehabilitation improves quality of life among cancer survivors, and rehabilitation services are under the development within the field of cancer care. Objectives: The aim of this presentation is to give an overview of the development and status of rehabilitation aimed at patients with cardiac diseases and to draw parallels to development of rehabilitation as part of comprehensive cancer care. Methods: The presentation will be based on systematic literature review supplemented with data from organizational and economic analysis. Results: The results will be presented with focus on the complex intervention of rehabilitation and the effect of the intervention. Further results demonstration the patient-perspective, organizational challenges and economic aspects of rehabilitation will be presented in the context of cardiac and cancer care. Conclusions: Parallel situations within the field of rehabilitation can be identified across the diagnostic entities of cardiac disease and cancer. The presentation will discuss what to consider in the process of developing rehabilitation services within cancer care based on learning from cardiac care.
Supportive Care in Cancer, 2015, Vol 23, Issue Suppl 1
*rehabilitation *cancer patient *human *neoplasm rehabilitation center patient heart disease quality of life cardiac patient solid mortality learning hospitalization diagnosis economic aspect cancer survivor; *osteoporosis *chemotherapy *breast cancer *neoplasm *risk human patient osteolysis hip spine adjuvant chemotherapy secondary osteoporosis radius bone density Fisher exact test cohort analysis drug therapy fracture cancer patient forearm absorptiometry X ray imaging cancer chemotherapy prednisolone corticosteroid marker calcium vitamin D; *overall survival *patient *human *neoplasm *Charlson Comorbidity Index stereotactic body radiation therapy comorbidity lung cancer non small cell lung cancer scoring system medical record review physician survival control group histology gender follow up smoking tumor volume data base; *central venous catheter *bloodstream infection *therapy *acute lymphoblastic leukemia *cohort analysis *Denmark *neoplasm human patient risk child attributable risk diagnosis death pediatric hospital confidence interval population high risk population neutropenia Gram positive infection; *hypothyroidism *radiotherapy *neoplasm thyroid gland neck human patient risk factor surgery radiation radiation dose planning model chemotherapy breast cancer subclinical hypothyroidism Hodgkin disease head and neck squamous cell carcinoma data extraction treatment planning thyroid function risk prediction tissues; *hospital *neoplasm pathogen load microorganism microbiology colony forming unit hospital infection photometer oncology ward *adenosine triphosphate marker; *hospital infection *neoplasm human patient oncology ward infection ward risk urinary tract diarrhea disease control bacteremia safety health care pneumonia serum hospitalization infection control surgical ward mouth hygiene prevention immune system; *radiotherapy *cohort analysis *larynx cancer *cancer patient *human *neoplasm *tobacco use smoking lowest income group diagnosis statistics head and neck cancer data base diseases tobacco primary tumor treatment response prognosis logistic regression analysis Denmark risk tobacco consumption patient world health organization; *myeloma *patient *human *neoplasm survival morbidity death kidney failure diagnosis scoring system quality of life hope disease severity infection; *neoplasm *risk human chemotherapy quality of life cancer survivor prevention single nucleotide polymorphism peripheral neuropathy predictive value side effect genomics glove detoxification genotype gene DNA repair genetic variability patient toxicity platinum derivative enzyme DNA; *neoplasm *human *vein thrombosis *patient thrombosis cancer patient risk questionnaire morbidity lung cancer cancer prevention death male prevention female; *overall survival *radiotherapy *non small cell lung cancer *neoplasm human patient survival radiation chemotherapy histology lung function thorax tumor squamous cell carcinoma lung cancer gender world health organization; *febrile neutropenia *cancer patient *human *neoplasm male female chemotherapy patient cerebrospinal fluid drug dose reduction risk aged prostate diagnosis Denmark prospective study ovary cancer university hospital oncology retrospective study density prognosis adverse drug reaction *granulocyte colony stimulating factor; *salivary gland function *radiation dose *salivary gland *radiotherapy *head and neck cancer *neoplasm salivation xerostomia stimulus chewing gum radiotherapy planning system side effect flow rate questionnaire prescription drug megadose human patient submandibular gland pilot study food saliva sugar; *side effect *human *retrospective study *neoplasm *eye disease patient eye non small cell lung cancer tear flow blurred vision conjunctivitis Denmark oncology toxicity quality of life university hospital clinical practice dry eye palliative therapy swelling skin *pemetrexed; *rehabilitation *interview *oncology ward *nursing *neoplasm human nurse patient intuition hospitalization oral communication hematology ward skill oncology verbal communication communication skill nursing competence questionnaire interpersonal communication; *human *cancer patient *neoplasm *spouse *radiotherapy *head and neck cancer patient diseases physician child friend hospital memory nutrition information processing; *human *phase 1 clinical trial *neoplasm *patient *rectum cancer *neuropathy *prevention neurotoxicity chemotherapy allodynia infusion peripheral neuropathy safety phase 2 clinical trial antineoplastic activity adverse drug reaction model toxicity experience controlled study *placebo oxaliplatin fluorouracil protective agent; *head and neck cancer *radiation *neoplasm mucosa inflammation risk proportional hazards model acceleration human regression analysis log rank test patient radiotherapy intensity modulated radiation therapy; *human *neoplasm *nurse *patient *skill *sexuality *hematology *oncology sexual dysfunction conversation health practitioner prevalence sexual orientation society cancer therapy interview sexual function literature counseling coping behavior